Global Leading Market Research Publisher QYResearch announces the release of its latest report “Medical Scalp Vein Set – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medical Scalp Vein Set market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6086235/medical-scalp-vein-set
The Peripheral Vascular Access Challenge: Why the Humble Scalp Vein Set Remains Indispensable
Venous access represents the most frequently performed invasive medical procedure globally, yet it harbors a persistent clinical paradox: the patients who need vascular access most urgently—neonates, infants, the elderly, oncology patients with depleted venous capital—are precisely those in whom conventional peripheral intravenous catheters are most difficult to place successfully. The medical scalp vein set, often referred to as a “butterfly needle,” addresses this challenge through a deceptively simple design innovation: a small-gauge needle integrated with flexible plastic wings that provide the clinician with precise control during insertion into small, fragile, or poorly visible veins, connected to a length of flexible tubing that decouples needle manipulation at the insertion site from syringe or infusion line attachment. The global Medical Scalp Vein Set market, valued at USD 761 million in 2025 and projected to reach USD 1,131 million by 2032 with a CAGR of 5.9% , reflects this device’s essential, non-substitutable role in the peripheral vascular access device armamentarium.
Device Architecture and Clinical Applications
The device is used for venipuncture in short-term infusion or blood collection, particularly suited for pediatric patients and adults with poor venous access. The distinguishing design feature—flexible wing-like extensions flanking the needle hub—enables a low-angle insertion technique that is especially advantageous for accessing the small, superficial veins of the scalp, hands, and feet that serve as primary venous access sites in neonates and infants. The wings provide a stable gripping surface for the clinician’s fingers and, once the needle is positioned within the vein, can be folded flat against the skin and secured with tape to provide temporary fixation without the catheter hub bulk that characterizes conventional over-the-needle peripheral IV catheters.
The market segmentation by product type reveals the industry’s response to evolving clinical and regulatory requirements. Winged Scalp Vein Sets represent the traditional design and the dominant volume segment, used for routine blood collection and short-term infusion in settings where the simplicity, low cost, and widespread clinical familiarity of the basic butterfly configuration align with procedural requirements. Safety Scalp Vein Sets represent the highest-growth segment, driven by the global regulatory trend toward mandating safety-engineered sharp devices. These devices incorporate mechanisms—retractable needles that withdraw into the device housing upon activation, hinged safety shields that cover the needle upon withdrawal from the vein, or passive safety designs that activate automatically without requiring clinician action—that reduce the risk of needlestick injury.
The safety device segment’s growth trajectory has been shaped by regulatory mandates including the European Union’s Council Directive 2010/32/EU on prevention of sharps injuries in the hospital and healthcare sector, and the U.S. Needlestick Safety and Prevention Act requiring the use of safety-engineered sharp devices. The World Health Organization’s global strategy on infection prevention and control continues to reinforce these national-level mandates. The supply side has responded comprehensively: a March 2025 academic review documented that safety-engineered needle devices including retractable butterfly needles are now commercially available from multiple manufacturers spanning global medical device corporations and regional producers, with the evidence base demonstrating clinically significant reductions in needlestick injury rates when safety devices replace conventional non-safety alternatives. Scalp Vein Sets with Extension Tubes provide the additional length between the venipuncture site and the connection point necessary for applications where direct syringe attachment at the needle hub would risk dislodgement, including scalp vein infusion in infants where head movement would otherwise transmit to the insertion site.
Application-Specific Requirements and Clinical Economics
The application segmentation reveals distinct procedural contexts. Intravenous Infusion accounts for the largest application volume, utilizing scalp vein sets for short-duration fluid and medication administration in patients where conventional IV catheters are either difficult to place or inappropriate. Venous Blood Collection represents the second major application, where the scalp vein set serves as the collection device for diagnostic phlebotomy in patients with difficult venous access. The flexibility advantage—the ability to manipulate the needle independently of the collection tube or syringe—is particularly valued in pediatric phlebotomy where vein size and patient movement magnify the technical difficulty of conventional straight-needle or evacuated tube holder collection. Short-term Injection completes the major application triad, covering bolus medication administration.
Exclusive Analysis: The Over-the-Needle Catheter vs. Scalp Vein Set Procedural Economics
A comparative dimension consistently underexamined in the vascular access literature is the divergent clinical economics of scalp vein sets versus conventional peripheral IV catheters. Over-the-needle catheters require higher unit cost, demand greater insertion skill, and carry the complication profile of extended dwell—phlebitis, infiltration, and catheter-related bloodstream infection—that scalp vein sets, removed upon procedure completion, avoid. For short-duration access scenarios, the scalp vein set offers a meaningfully lower total procedure cost. This economic dynamic is particularly consequential in developing healthcare systems facing dual pressures of expanding healthcare access and containing per-capita expenditure, and in value-based reimbursement environments where procedure-related complications impose financial penalties. A 2024 health economic analysis demonstrated that for infusion durations under four hours, scalp vein sets achieved cost savings while maintaining equivalent clinical effectiveness to short peripheral IV catheters—a finding with implications for procurement protocol optimization in high-volume short-stay surgical and emergency department settings.
Competitive Landscape and Regional Dynamics
The competitive landscape features major global medical device manufacturers alongside regional producers. B. Braun Melsungen AG, Terumo Corporation, Becton, Dickinson and Company, Nipro Corporation, and Smiths Medical command premium positioning through product portfolios spanning the full peripheral vascular access range, safety device intellectual property portfolios, and established hospital group purchasing organization contracts. Vygon Group, Poly Medicure, and WEGO Group compete through specialized product offerings and regional market positions. Indian manufacturers including Angiplast and Bain Medical Equipment have expanded market presence through competitive pricing and progressively improving safety device technology. Regionally, Asia-Pacific commands growth leadership driven by expanding healthcare infrastructure, increasing procedure volumes, and progressive adoption of safety device mandates aligned with maturing regulatory frameworks.
The projected 5.9% CAGR through 2032 reflects durable demand infrastructure: the irreducible volume of venipuncture procedures globally, the expanding safety device transition creating a multi-year replacement cycle, healthcare access expansion in developing economies, and the concentration of clinical need in pediatric and geriatric populations where scalp vein sets remain the vascular access device of choice.
The Medical Scalp Vein Set market is segmented as below:
B. Braun Melsungen AG
Terumo Corporation
Becton, Dickinson and Company
Nipro Corporation
Smiths Medical
Medline Industries
Cardinal Health
Vygon Group
Angiplast Pvt. Ltd.
Poly Medicure Ltd.
Bain Medical Equipment
Vogt Medical
WEGO Group
Segment by Type
Winged Scalp Vein Set
Safety Scalp Vein Set
Scalp Vein Set with Extension Tube
Others
Segment by Application
Intravenous Infusion
Venous Blood Collection
Short-term Injection
Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
